Millions of patients now able to benefit from Medicare approved test

Congratulations to a Vanderbilt research collaborator on receiving Medicare approval of a diagnostic test for patients with advanced non-small cell lung cancer (NSCLC).


 


Biodesix, the molecular diagnostic company that owns VeriStrat, shared the news via press release:


Biodesix Secures Medicare Coverage for VeriStrat® Test:  Coverage of Predictive Biomarker Test Enables Lung Cancer Patients to Benefit From More-Informed Treatment Decisions


 


Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that Novitas Solutions, the Medicare Administrative Contractor for the region that includes Colorado, has established coverage for the company’s VeriStrat test. VeriStrat, a clinically validated blood-based protein test, helps physicians guide second-line therapy for patients with advanced non-small cell lung cancer (NSCLC). The coverage decision means that more than 49 million eligible Medicare enrollees in the U.S. will now be able to benefit from VeriStrat being a covered diagnostic test, according to specific lung cancer indications outlined by Novitas.


 


Click here to read the full release.